Close Menu
Home › SpeeDx, UgenTec Collaborate on Interpretation for Infectious Disease Dx Results

SpeeDx, UgenTec Collaborate on Interpretation for Infectious Disease Dx Results

Jan 16, 2017

NEW YORK (GenomeWeb) – Australian diagnostics firm SpeeDx has announced that Belgian software maker UgenTec will provide interpretation for results generated by the firm's infectious disease diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13
Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
18
Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19
Featured Webinar

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jun
25
Featured Webinar

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

In Molecular Diagnostics

  1. Guardant Health Plans Public Offering of 4.5M Shares

  2. Biocept Shares Skyrocket on Commercial Launch of Lung Cancer Liquid Biopsy Test

  3. Startup GenomeSmart to Address Lack of Genetic Testing Knowledge With Digital Solution

    Premium

  4. NeoGenomics Prices $149M Public Offering of Common Stock

  5. Biocept Targets Pathologists, Naturopaths to Drive Liquid Biopsy Adoption

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.